Beta

Spending
Congress
Stocks
Lobbying

Spending
Congress
Stocks
Lobbying

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Congress
Stocks
Lobbying

LD-2 disclosure · 1st Quarter - Report

ALNYLAM PHARMACEUTICALS

via THE MCMANUS GROUP

1st Quarter (Jan 1 - Mar 31) · 2021Posted Apr 20, 2021Filing document ↗LDA record ↗

Income$60Kfee reported

Client

Name: ALNYLAM PHARMACEUTICALS
Description: Biopharmaceutical company
Location: Massachusetts · United States of America

Registrant

Firm: THE MCMANUS GROUP
Description: Consulting
Location: Washington, District of Columbia, United States of America

Lobbying activities

1 issue

Medicare/Medicaid
Medicare CY 2021 Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) Policy Issues and Healthcare Common Procedure Coding System (HCPCS) Level II Proposed Rule (CMS-1738-P). Provisions related to vial wastage rebates in Part B. Implementation of Home Infusion Therapy Benefit.
LobbyistsJOHN MCMANUS · ALANNA TEMME
Covered position (JOHN MCMANUS): Staff Director W&M Health Subcommittee; LA, Rep. Bill Thomas
Covered position (ALANNA TEMME): LD, Rep. Jon Porter
TargetedSENATE · HOUSE OF REPRESENTATIVES

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.

ALNYLAM PHARMACEUTICALS — Lobbying — Receipts Report